CD8A and type 1 diabetes mellitus: Our initial attempts at developing an antigen-specific therapeutic approach for type 1 diabetes (T1D) aimed at triggering the deletion of a highly prevalent and diabetogenic CD8+ T-cell population specific for residues 206–214 of the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP206–214).